Scholarlink

Background <p>Despite the rise of cancer immunotherapy, cisplatin remains a cornerstone in chemotherapy. Hyponatremia is a common but under-recognized adverse event of cisplatin. Previous studies on cisplatin-induced hyponatremia (CIH) are limited and mostly focus on the initial administration. This study aimed to assess the overall incidence of CIH and identify significant predictive factors.</p> Methods <p>We conducted a single-center, retrospective cohort study of patients who received intravenous cisplatin at Juntendo University Hospital between 2018 and 2020. The occurrence and severity of CIH were assessed across all administrations. Predictive factors were analyzed using multiple logistic regression and generalized linear mixed models.</p> Results <p>Among 706 patients, 340 (48.2%) experienced CIH during the study period, with 103 (14.6%) developing Grade 3 or higher severity. Across 1939 total cisplatin administrations, CIH occurred in 585 (30.2%) cases, including 135 (7.0%) with Grade ≥ 3 severity. CIH was most common at first administration (38.8%), with severe cases occurring in 11.9%. Generalized linear mixed models results that the significant prognostic factors for cisplatin-induced Hyponatremia were age (OR: 1.41, p &lt; 0.001), last cisplatin dose (OR: 1.74, p &lt; 0.001), serum albumin (OR: 0.65, p &lt; 0.001), serum sodium (OR: 0.35, p &lt; 0.001), WBC (OR: 1.26, p = 0.01), and concomitant 5-FU administration (OR: 3.91, p &lt; 0.001).</p> Conclusions <p>CIH is a frequent and potentially serious complication of cisplatin therapy. Older age, high-dose cisplatin, hypoalbuminemia, hyponatremia, leukocytosis, and 5-FU co-administration significantly increase the risk. These findings highlight the importance of proactive monitoring and management strategies to mitigate CIH risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice

  • 期刊论文

  • 发表日期：

    2026年7月24日

查看全文
  • Yuki Nagashima,
  • Satoru Muto,
  • Yosuke Shimada,
  • Shigeo Horie

摘要

Background

Despite the rise of cancer immunotherapy, cisplatin remains a cornerstone in chemotherapy. Hyponatremia is a common but under-recognized adverse event of cisplatin. Previous studies on cisplatin-induced hyponatremia (CIH) are limited and mostly focus on the initial administration. This study aimed to assess the overall incidence of CIH and identify significant predictive factors.

Methods

We conducted a single-center, retrospective cohort study of patients who received intravenous cisplatin at Juntendo University Hospital between 2018 and 2020. The occurrence and severity of CIH were assessed across all administrations. Predictive factors were analyzed using multiple logistic regression and generalized linear mixed models.

Results

Among 706 patients, 340 (48.2%) experienced CIH during the study period, with 103 (14.6%) developing Grade 3 or higher severity. Across 1939 total cisplatin administrations, CIH occurred in 585 (30.2%) cases, including 135 (7.0%) with Grade ≥ 3 severity. CIH was most common at first administration (38.8%), with severe cases occurring in 11.9%. Generalized linear mixed models results that the significant prognostic factors for cisplatin-induced Hyponatremia were age (OR: 1.41, p < 0.001), last cisplatin dose (OR: 1.74, p < 0.001), serum albumin (OR: 0.65, p < 0.001), serum sodium (OR: 0.35, p < 0.001), WBC (OR: 1.26, p = 0.01), and concomitant 5-FU administration (OR: 3.91, p < 0.001).

Conclusions

CIH is a frequent and potentially serious complication of cisplatin therapy. Older age, high-dose cisplatin, hypoalbuminemia, hyponatremia, leukocytosis, and 5-FU co-administration significantly increase the risk. These findings highlight the importance of proactive monitoring and management strategies to mitigate CIH risk.